Book a consultation with Dr
OSU-T315: a novel targeted therapeutic that antagonizes AKT membrane localization and activation of chronic lymphocytic leukemia cells
Identifying GLP-1s: This analysis includes all Medicaid prescriptions and gross spending for any FDA-approved GLP-1s
27 This is in contrast to exenatide, which is primarily eliminated through the kidneys, and is not recommended for use in patients with severe renal impairment or in those with end-stage renal disease (ESRD)
Among currently available agents, GLP-1 RAs - and tirzepatide in particular, based on the SURMOUNT-1 subgroup analysis - have the most substantial weight-loss evidence in this population, with efficacy appearing comparable to that observed in common obesity
Instead, it supports natural satiety and mindful eatingmaking it easier to build sustainable habits rather than relying solely on the medication to do the work. 3